Close
Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
Show source BACK TO LIST

Laboratory Report

Patient
Name: Almila, Ulpu
DOB: 03-SEP-1993 (Age: 32)
Gender: female
Address:
Viru 51
94764 Tupenurme (Estonia)
ID: 9847-452473-7
Report
Date: 14-APR-2024
Laboratory
Requested by
Emmaste Kliinik
92412 Hiiumaa vald (Estonia)
Specimen
Collected: 13-APR-2024

Chemistry

Test 13 Apr 2024 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 6.1 H 4.8 - 5.7 %
Glucose [Mass/volume] in Blood 72.6 70 - 99 mg/dL
Urea nitrogen [Mass/volume] in Blood 19.6 7 - 50 mg/dL
Creatinine [Mass/volume] in Blood 0.9 0.6 - 1.1 mg/dL
Calcium [Mass/volume] in Blood 9.8 8.5 - 10.4 mg/dL
Sodium [Moles/volume] in Blood 137.8 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.4 3.5 - 5 mmol/L
Chloride [Moles/volume] in Blood 104.9 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 26.8 24 - 29 mmol/L

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows persistently elevated HbA1c (6.1% and 5.9%), indicating impaired glucose metabolism or possible prediabetes, despite normal to low fasting glucose. Renal function, electrolytes, and other parameters are within normal limits. Recommend further evaluation for glycemic control and consideration of lifestyle or therapeutic interventions to prevent progression to diabetes.